Why Michael Burry Just Trimmed His Only Holding To Buy These 5 Stocks? 4 Are Down Big & 1 Is Soaring

Michael Burry's Portfolio Shift

• 💡 Michael Burry dramatically trimmed his Estee Lauder position by 25% in Q1 2025, reallocating capital into five new stock investments.
• 🎯 This move reflects his contrarian investment philosophy, seeking opportunities when the market consensus has given up and individual stocks are undervalued.
• 📈 Four of the newly acquired stocks were down significantly (20-50% YTD), while one was up 36% YTD, indicating a "buy the dip" strategy amidst a strong S&P 500.

Lululemon Athletica (LULU)

• 🧘‍♀️ Burry sees opportunity in Lululemon, despite its stock being hammered by macro headwinds like cautious consumer trends and steep tariffs.
• 🚀 The company boasts a powerful business model with high-margin products, strong brand equity, robust international growth (especially in China), and effective supply chain diversification.
• ✅ Lululemon generates strong free cash flow, enabling global expansion, margin protection, and share buybacks, signaling management's confidence.

Bruker Corporation (BRKR)

• 🔬 Bruker, a leader in advanced life sciences equipment, faced headwinds from NIH funding cuts and economic uncertainty, causing its stock to drop.
• 💡 Burry's investment suggests a belief in its long-term potential, driven by diversification into higher-margin consumables and reagents, and significant cost-saving initiatives.
• 📊 The company's technology leadership in nuclear magnetic resonance and its current low valuation present a classic mean reversion opportunity for patient investors.

Regeneron Pharmaceuticals (REGN)

• 💊 While the market focuses on the decline of its drug Eylea, Regeneron's growth engine is strong, particularly with its blockbuster immunology drug Dupixent achieving significant sales growth.
• 🌱 The biotech powerhouse is expanding its oncology portfolio with drugs like Libtayo and Linvoseltamab, and making strategic bets in obesity therapeutics.
• 💰 Regeneron maintains a strong financial position with over $17 billion in cash, supporting R&D and acquisitions, making its current valuation attractive to contrarian investors.

Mercado Libre (MELI)

• 🛍️ Mercado Libre, often called the "Amazon of Latin America," is also a fintech powerhouse through Mercado Pago, driving significant revenue growth across its markets.
• 📈 The company is strategically sacrificing near-term margins for long-term growth by expanding free shipping and marketing, solidifying customer loyalty and market dominance.
• 🌎 With strong growth, strategic reinvestment, and an underpenetrated digital payments market in Latin America, Mercado Libre represents a high-conviction bet.

UnitedHealth Group (UNH)

• 🏥 UnitedHealth Group experienced a stock tumble due to a CEO resignation and a DOJ investigation into Medicare fraud, alongside rising Medicare Advantage costs.
• 💰 Despite these challenges, the company's consistent dividend increase (5.2%) reflects confidence in its underlying cash flow and financial resilience.
• 📊 Burry's investment points to a belief that short-term fear is overshadowing strong long-term fundamentals, with the stock trading at a valuation discount and possessing unmatched scale.